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Abstract
Background: The epidermal growth factor (EGF) family of ligands has been implicated in promoting breast cancer
initiation, growth and progression. The contributions of EGF family ligands and their receptors to breast cancer are
complex, and the specific mechanisms through which different ligands regulate breast tumor initiation and growth
are not well-defined. These studies focus on the EGF family member epiregulin (EREG) as a mediator of early stage
breast tumorigenesis.
Methods: EREG expression levels were assessed in both cell lines and human samples of ductal carcinoma in situ
(DCIS) using quantitative RT-PCR, ELISA and immunohistochemistry. Gene knock-down approaches using shRNA-based
strategies were used to determine the requirement of EREG for growth of MCF10DCIS cells in vivo, and for identifying
mechanisms through which EREG promotes tumor cell survival. Experiments were performed using a combination of
two-dimensional culture, three-dimensional culture and tumor growth in vivo.
Results: In comparison with other EGF family members, EREG was induced in MCF10DCIS cells compared with
MCF10A and MCF10AT cells and its expression was partially regulated by fibroblast growth factor receptor (FGFR)
activity. Reduced EREG expression in MCF10DCIS cells led to decreased tumor growth in vivo, which was associated
with reduced cell survival. Furthermore, treatment of MCF10A cells with exogenous EREG enhanced cell survival both
in three-dimensional culture and in response to chemotherapeutic agents. Examination of EREG-induced signaling
pathways demonstrated that EREG promoted survival of MCF10A cells through regulating expression of matrix
metalloproteinase-1 (MMP-1). To determine the relevance of these findings in human tumors, samples of DCIS
were analyzed for EREG and MMP-1 expression. EREG was induced in DCIS lesions compared to normal breast
epithelium, and EREG and MMP-1 were correlated in a subset of DCIS samples.
Conclusions: Together, these studies lead to identification of a novel pathway involving EREG and MMP-1 that
contributes to the formation of early stage breast cancer. Understanding these complex pathways could ultimately
lead to the development of novel biomarkers of neoplastic progression and/or new therapeutic strategies for patients
with early stage cancer.
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Introduction
The earliest stages of malignant transformation require
the acquisition of multiple phenotypes, such as prolifer-
ation, survival and migration, which contribute to
tumor growth and progression [1]. Identifying the key
cellular and molecular factors that drive the formation
of early breast cancer lesions will ultimately result in
the development of preventive approaches for patients
that are at high risk for developing invasive breast can-
cer. Furthermore, as methods for detecting breast
lesions become increasingly sensitive, the successful
identification of markers associated with early lesions
could lead to better prognostic indicators and/or the
development of patient-tailored therapies that inhibit
malignant progression [2].
Aberrant activation of the ErbB family of growth
factor receptors and their downstream signaling path-
ways has been implicated in breast cancer initiation
and maintenance [3]. Activation of ErbB receptors in
cancer occurs through various mechanisms, including
mutation, amplification and regulation of epidermal
growth factor (EGF)-family ligands and cross-talk with
other signaling pathways [3–7]. Several EGF ligands
have been implicated in breast cancer, including EGF,
epiregulin (EREG), amphiregulin (AREG), heparin-
bound EGF (HB-EGF) and transforming growth factor
alpha (TGFα) [8–14]. We focus here on EREG, which
we demonstrate is increased in ductal carcinoma in situ
(DCIS) compared with non-transformed breast epithe-
lium. Previous studies found detectable levels of EREG
mRNA in up to 45.5 % of breast cancer and EREG has
been linked to pulmonary metastasis in experimental
studies [13, 15, 16]. However, the contributions of
EREG to early stages of breast tumor initiation and
growth have not been investigated.
We demonstrate here that EREG regulates expression of
matrix metalloproteinase-1 (MMP-1) in non-transformed
breast epithelial cells and in a model of DCIS. MMP-1 is
an interstitial collagenase that has been implicated in
breast cancer progression [17, 18]. Expression of MMP-1
was found to be higher in atypical ductal hyperplasia
(ADH) from patients that progressed to invasive breast
cancer than those from patients that did not progress [19].
Furthermore, high levels of MMP-1 expression are associ-
ated with poor prognosis [17] and increased risk of bone
metastasis in breast cancer patients [20]. While it is well
documented that MMP-1 cleaves extracellular matrix
molecules, such as collagen [21, 22], MMP-1 has also been
linked to the promotion of cell survival [23, 24], suggest-
ing that MMP-1 may contribute to multiple processes
during tumor growth and progression.
In the studies described here, we demonstrate that
EREG expression is increased in early stage breast can-
cer lesions. Furthermore, we use both two-dimensional
(2D) and three-dimensional (3D) cell culture assays to
demonstrate that EREG acts through induction of MMP-1
to confer survival advantages to non-transformed mam-
mary epithelial cells. Finally, we demonstrate that loss of
EREG expression in transformed breast cancer cells leads
to reduced tumor growth in vivo, which is associated with
increased tumor cell apoptosis. Based on these studies, we
propose that EREG contributes to the formation of pre-
invasive lesions in a subset of breast cancers. Identifying
novel mechanisms through which early stage breast can-
cers arise has important implications for identification of
biomarkers of aggressive disease and development of
novel therapeutic strategies.
Results
Identification of EREG as a potential mediator of early
stage breast cancer
EGF ligands and their receptors are well-established
mediators of breast cancer growth and progression [3–5,
7]. Lee et al. demonstrated that expression levels of both
AREG and EREG were increased in hyperplastic enlarged
lobular units compared to normal epithelium isolated
from human breast samples, suggesting differential regula-
tion of EGF ligands during the earliest stages of tumor ini-
tiation [10]. Thus, an initial screen of EGF ligand
expression was performed in MCF10A cells, which repre-
sent non-transformed breast epithelial cells, and
MCF10DCIS cells, which were derived from MCF10A
cells and form tumors that have characteristics of
comedo-type DCIS in vivo [25]. qRT-PCR was per-
formed to assess expression levels of EREG, AREG,
EGF, HB-EGF and TGFα, all of which have been impli-
cated in breast cancer [8, 10–14]. Expression levels of
EGF and TGFα were not changed between the two cell
lines (Fig. 1a). AREG and HB-EGF were increased ap-
proximately 8-fold in the MCF10DCIS cells compared
with MCF10A cells (Fig. 1a). However, EREG expres-
sion levels were found to be increased over 100-fold in
MCF10DCIS cells compared with MCF10A cells
(Fig. 1a). EREG is expressed as a transmembrane pro-
tein and is shed into the media by cell surface proteases
[26–28], thus soluble EREG is detectable by ELISA. As
shown in Fig. 1b, a significant increase in EREG was
found in conditioned media obtained from MCF10DCIS
cells compared with media from MCF10A cells.
To assess EREG expression in additional breast
cancer cell lines, EREG expression levels were exam-
ined in additional cell lines including MCF10AT, an
HRAS-transformed derivative of the MCF10A cell line,
MCF7, an estrogen receptor positive cell line, SUM225,
another cell line capable of forming DCIS-like lesions
in vivo and MDA-MB-231, a triple negative invasive
cell line. EREG was found to be highest in the
MCF10DCIS and SUM225 cells, compared with the
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other cell lines (Fig. 1c). These findings are consistent
with the hypothesis that EREG may be induced in early
stages of breast cancer.
In previously published studies, we demonstrated that
EGF ligands, including EREG, are regulated by FGFR
signaling [29]. To examine whether FGFR activity is linked
to the increase in EREG expression in MCF10DCIS cells,
cells were treated with the FGFR-selective inhibitor doviti-
nib. FGFR inhibition led to a decrease in pFRS2, a down-
stream substrate of FGFR (Fig. 1d), and a significant
decrease in EREG expression in a dose dependent manner
(Fig. 1e). Notably, the concentration of dovitinib used (5
nM and 10nM) was within the range of specificity for
FGFRs [30, 31]. To identify the mechanism through which
FGFR is activated in these cells, qRT-PCR analysis was
performed to examine expression levels of FGF ligands in
serum starved MCF10A and MCF10DCIS cells. Of the 22
ligands examined, two were found to be increased in
MCF10DCIS cells more than 2-fold, including FGF-2,




Fig. 1 Regulation of EREG expression in MCF10DCIS cells by FGFR activity. a qRT-PCR of the indicated EGF ligands was performed on RNA isolated from
MCF10A cells and MCF10DCIS cells. Expression levels were normalized to levels of CYBP. b Soluble levels of EREG in conditioned media obtained from
MCF10A and MCF10DCIS cells as determined by ELISA. c qRT-PCR of the EREG expression was performed on RNA isolated from the indicated
cell lines. d Immunoblot analysis was performed to examine the effects of the indicated amounts of dovitinib on phosphorylation of FRS-2 in
MCF10DCIS cells. e Concentration of EREG in conditioned media, as determined by ELISA, from MCF10DCIS cells treated with the indicated
amounts of dovitinib for 18 h. f qRT-PCR analysis of FGF-2 expression in MCF10A and MCF10DCIS cells. Levels normalized to CYBP. *p < 0.05,
**p < 0.001, ***p < 0.0001
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was increased 2-fold (data not shown). These results sug-
gest that EREG is regulated, in part, as a result of auto-
crine FGFR activation in MCF10DCIS cells.
Reduced expression of EREG in MCF10DCIS cells leads to
decreased cell survival
Based on the finding that EREG expression is significantly
enhanced in MCF10DCIS compared with MCF10A cells,
further studies were performed to determine the contribu-
tions of EREG to MCF10DCIS tumor growth. For these
studies, EREG gene expression was knocked down in
MCF10DCIS cells using a tetracycline-inducible shRNA.
Of the four constructs tested, two constructs were chosen
for further study based on significant knock-down of
EREG expression (Fig. 2a). Effects of EREG knock-down
on growth of MCF10DCIS cells were initially evaluated in
three-dimensional culture. Cells expressing either non-
targeting shRNA or an EREG shRNA were plated in
Matrigel and allowed to establish for 4 days. The struc-
tures were then treated with doxycycline for an additional
6 days and effects on acinar diameter were measured. Loss
of EREG led to a decrease in overall acinar size of
MCF10DCIS cells (Fig. 2b,d), which correlated with in-
creased apoptosis as determined by TUNEL (Fig. 2c,d).
To assess the effects of loss of EREG expression on
tumor growth, MCF10DCIS cells expressing either
non-targeting shRNA or EREG shRNA were implanted
subcutaneously into nude mice. Once the tumors
reached a size of 100 mm3, the mice were administered
doxycycline to induce shRNA expression. As shown in
Fig. 3a, reduced EREG expression using both shRNA
constructs led to a significant reduction in tumor
growth. Despite this reduction in tumor size, the histo-
logic appearance of both control and EREG knockdown
tumors was similar (Fig. 3b). Histologic sections from
both experimental conditions demonstrated tumor cells
growing in tightly packed, solid nests of variable size.
Smaller nests exhibited myoepithelial cells consistent
with an in situ component while larger nests and solid




Fig. 2 Decreased expression of EREG leads to reduced acinar growth in vitro. a MCF10DCIS cells were transduced with either non-targeting (NT)
or two different EREG shRNA constructs. Expression levels of EREG were determined by qRT-PCR and normalized to levels of CYBP. b Quantification of
acinar size. c Quantification of apoptotic structures. d MCF10DCIS cells expressing either NT shRNA or shEREG were plated in Matrigel and allowed to
establish for 4 days followed by treatment with 1 μg/ml doxycycline for an additional 4 days. Upper panels show images obtained by light microscopy.
Lower panels show apoptotic cells within structures visualized by TUNEL staining. Scale bars represent 200 μm. *p < 0.01, **p < 0.005
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desmoplastic stroma consistent with a pushing, invasive
border. Comedo-type necrosis with acute inflammation
was moderate to widespread, and mitotic figures were
abundant. Overall, no single morphologic characteristic
could reliably differentiate control from EREG knock-
down tumors, and the appearance was highly consistent
with previously published reports of the MCF10DCIS
xenograft tumors [25]. Despite the morphologic
similarity based on H&E staining, immunoblot analysis
of tumor lysates demonstrated that loss of EREG was
associated with decreased phosphorylation of EGFR
(Fig. 3c). While there was no difference in tumor cell
proliferation as determined by BrdU incorporation
(data not shown), there was a significant increase in
apoptosis in the tumors expressing EREG shRNA as





Fig. 3 Decreased expression of EREG leads to reduced tumor growth in vivo. a 50,000 MCF10DCIS-shNT, MCF10DCIS-shEREG1 or
MCF10DCIS-shEREG1 cells were injected subcutaneously into nude mice. Once tumors reached 100 mm3, mice were provided doxycycline.
Tumors were measured every other day. b Tumors harvested, sectioned and stained with hematoxylin and eosin (H&E). TUNEL analysis was
performed to identify apoptotic cells (green). Scale bars represent 50 μm. c Immunoblot analysis was performed on protein samples isolated from
pooled tumors to detect pEGFR. Immunoblotting of total EGFR was performed to assess equal loading. d Quantification of TUNEL-positive cells
in tumors from (a). n = 4 tumors per construct. *p < 0.05, **p < 0.005, ***p < 0.0001
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together, these results demonstrate that loss of EREG
leads to reduced cell survival in vivo.
EREG promotes cell survival of MCF10A cells in an MMP-1
dependent manner
In addition to knock-down experiments in MCF10DCIS
cells, the consequences of enhancing EREG-mediated sig-
naling in both MCF10A and MCF10AT cells were
examined. Studies were performed in 3D culture to
examine effects of EREG on epithelial morphogenesis.
When plated in recombinant basement membrane matrix,
MCF10A cells undergo both proliferation and apoptosis to
form acinar-like structures [32]. MCF10A and MCF10AT
cells were plated in recombinant basement membrane and
allowed to grow for 8 days in the presence of either
rhEREG or PBS as a solvent control. There was a moderate
but significant increase in acinar size when MCF10A cells
were grown in the presence of rhEREG (Fig. 4a,b). Further
analysis of proliferation and apoptosis in these structures
revealed that there was no increase in proliferation as deter-
mined by phospho-histone H3 staining (data not shown).
However, there was a significant decrease in apoptosis as
determined by staining structures for cleaved caspase-3
(Fig. 4a,c). As an additional control, similar studies were
performed using the MCF10AT cells, which were trans-
formed using an activated HRAS [33] and also express
relatively low levels of EREG (Fig. 1c). Treatment of
MCF10AT cells with EREG led to an increase in size of ac-
inar structures that was more robust than the induction in
size of the MCF10A structures (Fig. 4a,d). Similarly, we
found a reduction in the percentage of apoptotic struc-
tures upon treatment with rhEREG (Fig. 4a,e).
A
B C D E
Fig. 4 EREG promotes survival of MCF10A cells in 3D culture and in response to chemotherapeutic agents. a MCF10A and MCF10AT cells were
plated in recombinant basement membrane in the presence of either 10 ng/ml rhEREG or solvent control (PBS). Light microscopy was used to
examine effects of EREG on acinar morphology. Structures were stained for cleaved caspase-3 (green) and DAPI (blue) and analyzed by confocal
microscopy. Scale bars represent 100 μm (MCF10A) and 200 μm (MCF10AT). b Quantification of acinar diameter of MCF10A structures.
c Quantification of MCF10A structures with at least one cleaved caspase-3 positive cell. d Quantification of acinar diameter of MCF10AT
structures. e Quantification of MCF10AT structures with at least one cleaved caspase-3 positive cell. *p < 0.05, **p < 0.001
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To identify potential mechanisms through which EREG
contributes to survival of MCF10A cells, a candidate gene
approach with a focus on target genes known to be associ-
ated with early stage breast lesions was taken. MMP-1 was
identified as a candidate gene of interest based on pub-
lished studies demonstrating that MMP-1 expression is
enhanced in pre-invasive lesions (ADH) that progress to
invasive breast cancers. Although MMP activity is
frequently attributed to invasion, MMP-1 has also been
linked to cell survival [23, 24], thus representing a reason-
able candidate gene for further analysis. Treatment of
MCF10A and MCF10AT cells with rhEREG led to in-
creased expression of MMP-1 gene expression and protein
expression, with a stronger induction in MMP-1 protein
observed in the MCF10AT cells (Fig. 5a,b). To assess the





Fig. 5 MMP-1 contributes to EREG-induced survival of MCF10A cells. a qRT-PCR analysis of MMP-1 gene expression in MCF10A and MCF10AT cells
treated with either solvent (PBS) or 10 ng/ml rhEREG. Expression levels of MMP-1 were normalized to levels of CYBP. b Immunoblot analysis of
MMP-1 protein in conditioned media obtained from MCF10A and MCF10AT cells following 24 h of rhEREG treatment. Loading was assessed by
Coomassie staining (Additional file 1: Figure S1A). c Immunoblot analysis of MMP-1 protein in conditioned media obtained from MCF10A cells
treated with either non-targeting (NT) or MMP-1 siRNA following 24 h of rhEREG treatment. Loading was assessed by Coomassie staining (Additional
file 1: Figure S1B). d Quantification of acinar diameter of structures. MCF10A cells were transfected with either NT or MMP-1 siRNA prior to plating in
recombinant basement membrane with either solvent (PBS) or 10 ng/ml rhEREG. e Quantification of apoptotic structures. Structures that were positive
for at least one cleaved caspase-3 positive cell were counted. f MCF10A cells were treated with non-targeting (NT) or MMP-1 siRNA, serum starved and
treated with solvent control (PBS) or with 10 ng/ml rhEREG in the presence or absence of 2 μM doxorubicin (Dox). Effects on apoptosis were assessed
by immunoblot analysis for cleaved caspase-3. β-tubulin is shown as a loading control. *p < 0.05, **p < 0.001, ***p < 0.0001
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MMP-1 expression was knocked down using siRNA strat-
egies (Fig. 5c). Knockdown of MMP-1 in MCF10A cells
abrogated the ability of rhEREG treatment to enhance aci-
nar size (Fig. 5d) and prevent apoptosis as evidenced by
increased levels of caspase-3 cleavage in 3D culture (quan-
tified in Fig. 5e). In addition to examining the effects of
EREG on morphogenesis, further studies were performed
to examine the effects of rhEREG on cell survival in re-
sponse to an apoptotic stimulus. MCF10A cells were
treated with the chemotherapeutic agent doxorubicin in
the presence and absence of rhEREG. While doxorubicin
induced apoptosis, as shown by enhanced expression of
cleaved caspase-3, the addition of rhEREG to the media
promoted resistance to doxorubicin-induced apoptosis
(Fig. 5f). Furthermore, MMP-1 knockdown in MCF10A
cells abrogated the ability of rhEREG treatment to prevent
doxorubicin-induced apoptosis as evidenced by increased
levels of caspase-3 cleavage (Fig. 5f). These studies suggest
that the EREG-MMP-1 pathway promotes survival of
MCF10A cells.
Correlation between EREG and MMP-1 expression in human
breast cancers
To determine whether loss of EREG expression correlated
with altered MMP-1 expression in MCF10DCIS cells,
MMP-1 expression was examined. Increased gene and
protein expression of MMP-1 was found in MCF10DCIS
cells compared with MCF10A cells (Fig. 6a,b). Analysis of
MMP-1 expression in MCF10DCIS cells with reduced
EREG expression demonstrated a decrease in MMP-1
expression (Fig. 6c). These results suggest that similar to
MCF10A cells, EREG also regulates expression of MMP-1
in MCF10DCIS cells.
Based on our findings in the MCF10A and MCF10DCIS
cells, we analyzed expression levels of both EREG and
MMP-1 in human DCIS lesions. Normal (n = 17) and
DCIS lesions (n = 31) were stained for EREG expression.
While 29.4 % of the normal samples showed expression of
EREG, 64.5 % of DCIS lesions expressed EREG (p < 0.05)
(Fig. 6d,f). Together, these results suggest that EREG ex-
pression is relatively low in non-transformed breast epi-
thelial cells, but that its expression increases in a
percentage of DCIS lesions. To determine whether EREG
and MMP-1 are coordinately expressed in human tumors,
the same normal and DCIS human samples were stained
with an antibody to MMP-1 and expression levels were
scored. We found that high levels of MMP-1 were found
in 48 % of samples and low/negative levels were found in
52 % of samples (Fig. 6e,g). Furthermore, there was a sig-
nificant correlation between EREG and MMP-1 expres-
sion (p = 0.011) with EREG being expressed in 70 % of the
MMP-1high tumors (Table 1). Thus, EREG and MMP-1 ex-
pression are positively correlated in a subset of DCIS
tumors.
Discussion
While there have been numerous studies focusing on the
consequences of EGFR activation in breast cancer [4, 5,
7], less is known regarding the specific mechanisms
through which the different EGF ligands promote early
breast cancer growth and progression. Based on findings
in which EREG was found to be highly upregulated in
MCF10DCIS cells in comparison with MCF10A cells, the
studies described here focus on determining the potential
contributions of EREG to early stages of breast tumor
formation. Expression profiling studies have suggested
that both EREG and AREG expression levels are enhanced
in early stage breast lesions compared with normal epithe-
lium [10]. Furthermore, EREG expression has been
suggested to be a marker of early stages of other types of
cancers, such as ovarian cancer [34]. Finally, mislocali-
zation of the EREG transmembrane protein, which is
typically expressed at the basolateral cell surface, to the
apical cell surface enhances transformation of epithelial
cells [28]. Thus, understanding how EREG might
contribute to early stages of tumorigenesis has the poten-
tial to lead to novel biomarkers of early stage disease or to
the development of preventive or therapeutic approaches.
Based on the finding that EREG was enhanced in
MCF10DCIS cells, initial studies were performed to
identify mechanisms driving enhanced EREG expres-
sion. Our work has focused primarily on identifying im-
portant FGFR-induced target genes that contribute to
pro-tumorigenic phenotypes. In previous studies, we
demonstrated that FGFR activation leads to increased
expression and production of EGF ligands, including
AREG and EREG, which act through EGFR to enhance
FGFR-mediated signaling [29]. Published microarray
studies of early breast lesions, specifically hyperplastic
enlarged lobular units, identified both AREG and EREG
as genes that were significantly induced in these lesions
[10]. Here we demonstrate that FGFR activation in
MCF10DCIS cells, possibly through increased produc-
tion of FGF ligands such as FGF-2, contributes at least
partially to the increase in EREG observed in these cells.
Previously published studies have demonstrated in-
creased production of FGF-2 as a mechanism for en-
hanced FGFR activity in triple negative breast cancers
[35]. Thus it is possible that similar mechanisms are
involved in early stage cancer as well.
We demonstrate that EREG signaling promotes cell
survival, which contributes to increased tumor volume
in vivo. While it is possible that the reduction in tumor
volume solely reflects an overall decrease in EGF ligand
concentration within the tumor, it is also possible that
EREG has distinct effects on tumor growth than the
other ligands. Treatment of non-transformed cells with
exogenous EREG reduced apoptosis in 3D culture, a
process that is critical for epithelial morphogenesis in
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this model [36]. In addition, EREG reduced sensitivity of
cells to chemotherapy. Together, these studies suggest
that EREG functions primarily to promote cell survival
in these cells. Using a candidate gene approach to iden-
tify potential EREG regulated genes that are associated
with both cell survival and pre-invasive lesions, we
found MMP-1 to be induced following EREG stimula-
tion of MCF10A cells. The studies described here link
MMP-1 directly to EREG-induced mammary epithelial





Fig. 6 EREG expression correlates with MMP-1 levels in human DCIS lesions. a qRT-PCR analysis of MMP-1 gene expression in MCF10A and
MCF10DCIS cells. Expression levels of MMP-1 are normalized to CYBP. b Immunoblot analysis of MMP-1 in conditioned media obtained from
MCF10A and MCF10DCIS cells. Loading was assessed by Coomassie staining (Additional file 1: Figure S1C). c qRT-PCR analysis of MMP-1
gene expression in MCF10DCIS cells expressing either NT or EREG shRNA constructs. Expression levels of MMP-1 are normalized to CYBP.
d Immunohistochemistry of normal breast tissue and DCIS stained with an anti-EREG antibody. Scale bars represent 50 μm. e Normal and
DCIS human samples were stained with an anti-MMP-1 antibody. Representative images of normal and varying levels of MMP-1 staining in
DCIS lesions are shown. f Quantification of the percent of samples staining positive for EREG. g Quantification of the percent of samples
staining positive for MMP-1. Scale bars represent 50 μm. *p < 0.05. ***p < 0.0001
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agents in 2D culture and during epithelial morphogen-
esis in 3D culture. These results suggest that MMP-1 ex-
pression may be important for promoting survival of
epithelial cells during tumor initiation. Furthermore,
high levels of MMP-1 expression in tumors may confer
resistance to chemotherapeutic treatments. Further stud-
ies are warranted to define the specific mechanisms of
MMP-1 action during these distinct processes.
The results from these studies suggest that early stage
tumor cells produce increased levels of EREG, and that
exogenous EREG is capable of enhancing survival of epi-
thelial cells even in the presence of serum and additional
EGF ligand in the context of 3D culture. This observa-
tion raises the possibility that increased levels of EREG
production by tumor cells could potentially affect neigh-
boring non-transformed epithelial cells. EREG was found
to significantly enhance survival of non-transformed epi-
thelial cells, leading to a possible model in which high
levels of EREG in the developing tumor microenviron-
ment may enhance tumorigenic properties of surround-
ing normal epithelium in a paracrine manner.
Analysis of EREG and MMP-1 expression in the TCGA
database did not reveal a significant association, possibly
due to the fact that these samples represent invasive breast
cancers, rather than early stage breast cancers. However,
expression of EGFR and MMP-1 demonstrate a significant
trend towards co-occurrence (p < 0.001), suggesting that
this pathway may be maintained in invasive breast cancers.
Conclusions
In summary, our studies have identified a novel pathway
that promotes early stages of tumorigenesis. While fur-
ther studies are required to fully implicate this pathway
in promoting the development of early stage lesions,
they provide a foundation with which to better under-




MCF10A cells were obtained from the American Type Cul-
ture Collection (ATCC) and were maintained in DMEM/
F12 (Lonza, Allendale, NJ) supplemented with 5 % horse
serum (Life Technologies, Carlsbad, CA), 20 ng/ml EGF
(Life Technologies), 0.5 μg/ml hydrocortisone (Sigma, St.
Louis, MO), 100 ng/ml cholera toxin (Sigma), 10 μg/ml
insulin (Akron Biotech, Boca Raton, FL), and 1 %
penicillin-streptomycin (Life Technologies). MCF10AT,
MCF10DCIS and SUM225 cells were obtained from Dr.
Fariba Behbod (University of Kansas Medical Center).
MCF10ATcells were maintained in the same media as used
for the MCF10A cells. MCF10DCIS cells were maintained
in DMEM/F12, 5 % horse serum, and antibiotic/antimyco-
tic (Life Technologies). 293 T cells were obtained from
ATCC and maintained in D-MEM supplemented with
10 % FBS and 1 % penicillin-streptomycin (Life Technolo-
gies). MCF7 and MDA-MB-231 cells were obtained from
ATCC and maintained as recommended. For treatment of
cells with EREG, cells were treated with 10 ng/ml recom-
binant human EREG (rhEREG) (1195-EP-025/CF; R&D
Systems, Minneapolis, MN). For inhibitor studies, cells
were treated with the indicated amounts of dovitinib
(TKI-258, LC Laboratories) or the appropriate amounts of
solvent control.
Immunoblot analysis
For signaling analysis, cells were lysed in radioimmuno-
precipitation assay (RIPA) buffer and 20 μg of protein
were analyzed using SDS-PAGE. The following anti-
bodies were used for immunoblotting: phospho-FRS2α
(3861), GAPDH (2118), β-tubulin (2146) pEGFR (2234)
and cleaved caspase 3 (9661) (Cell Signaling, Danvers,
MA). To analyze MMP-1 by immunoblot analysis,
conditioned medium was collected from MCF10A and
MCF10DCIS cells and MMP-1 expression was deter-
mined (MAB901, R&D Systems). Equal amounts of con-
ditioned media were analyzed and loading was examined
by staining the gels with Coomassie and full gel images
are included in Additional file 1: Figure S1.
Epiregulin ELISA
Equal numbers of MCF10A and MCF10DCIS cells were
plated in growth media for 24 hours and serum starved
for an additional 24 h. The media was replaced with
serum free media and the concentration of EREG in the
conditioned media was determined 24 h later using the
Human EREG ELISA according to the manufacturer’s
protocol (Biosource).
Quantitative reverse transcription PCR(qRT-PCR)
RNA was extracted from cells using Trizol (Life Tech-
nologies) as described in the manufacturer’s protocol.
cDNA was made using the iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA) as described in the manufac-
turer’s protocol. Quantitative RT-PCR was performed
using iQ SYBR green supermix (Bio-Rad) and the Bio-
Rad iQ5 system. The 2-ΔΔCt method [37] was used to
determine the relative quantification of gene expression,
which was normalized to cyclophilin B (CYBP). Primer
sequences are listed in Additional file 2: Table S1.
Table 1 MMP-1 expression by EREG expression
Low EREG High EREG
No MMP-1 5 (45.5 %) 2 (10.0 %)
Low MMP-1 5 (45.5 %) 4 (20.0 %)
High MMP-1 1 (9.0 %) 14 (70.0 %)
p-value for the association between EREG and MMP-1 expression = 0.011
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Three-dimensional culture assay
2500 MCF10A cells or MCF10AT cells were plated on
growth factor reduced Matrigel (BD Biosciences, San
Jose, CA) as described [32] and treated with PBS or
10 ng/ml rhEREG on the day of plating (day 0). Images
were taken at 20X and acinar diameter was calculated
on day 8. For detecting apoptosis, cultures were fixed
with 2 % paraformaldehyde on day 5 and stained with
cleaved caspase-3 (9661; Cell Signaling) as described
[32] and mounted with ProLong Gold with DAPI (Life
Technologies). MCF10DCIS cells expressing non-
targeting shRNA or shRNAs specific for EREG were
plated into Matrigel in the same media used for the
MCF10A cells [32] and allowed to establish for 4 days.
Structures were treated with 1 μg/ml doxycycline for an
additional 6 days prior to imaging, fixing and staining as
described above. Confocal images were taken at the con-
focal microscopy facility at the University of Minnesota
Masonic Cancer Center.
Gene knockdown
MMP-1 was transiently knocked down in MCF10A cells
using siRNA approaches. Human MMP-1 and non-
targeting (NT) ON-TARGETplus SMART-pool siRNAs
(Dharmacon, Lafayette, CO) were used according to
manufacturer’s protocols. Knockdown was confirmed by
immunoblot analysis using conditioned media. For de-
tecting apoptosis in the cells with MMP-1 knockdown,
cells were treated with siRNA for 24 h and then plated
in Matrigel and analyzed as described above. Stable
knock-down of EREG in MCF10DCIS cells was obtained
by retroviral transduction of cells with EREG shRNA or
non-targeting (NT) tetracycline-inducible TRIPZ vectors
(Open Biosystems, Pittsburgh, PA). Briefly, 293 T cells
were transfected with the indicated constructs using the
Trans-Lentiviral Packaging System (Open Biosystems,
Pittsburgh, PA). MCF10DCIS cells were transduced with
the virus-containing media and stable cells were selected
using 2.5 μg/ml puromycin. shRNA expression was
induced by doxycycline (1 μg/ml) as indicated.
Tumor studies
FOXN1Nu athymic nude mice (Harlan Laboratories,
Indianapolis, IN) were injected subcutaneously with
MCF10DCIS expressing non-targeting or EREG shRNA
(50,000 cells in 50 μl of 50 % Matrigel [38]). Subcutane-
ous injections were performed rather than orthotopic
transplantation due to the need for consistent detection
of early tumors (100 mm3) prior to shRNA induction by
doxycycline. Mice were palpated and measured using
calipers. Once tumors reached 100 mm3, mice were
given 2 g/kg doxycycline in the chow (Harlan Labora-
tories) to induce EREG knockdown. After 11 days,
mice were sacrificed and tumors were fixed in 4 %
paraformaldehyde for 2 h embedded in paraffin and cut
to 5 μm sections for histological analysis by staining
with hematoxylin and eosin. Four tumors were ana-
lyzed per shRNA construct. All animal care and proce-
dures were approved by the Institutional Animal Care
and Use Committee of the University of Minnesota and
were in accordance with the procedures detailed in the
Guide for Care and Use of Laboratory Animals.
Immunohistochemistry and immunofluorescence
Antigen retrieval was performed on tissue sections
using a sodium citrate based buffer (Vector Laborator-
ies, Burlingame, CA). Tissues were blocked with 5 % BSA/
0.5 % Tween and incubated with primary antibodies over-
night. For immunohistochemistry with MMP-1 (MAB901;
R&D Systems) and EREG (AF1195; R&D Systems) and bio-
tinylated anti-mouse or anti-goat secondary antibody (Vec-
tor Laboratories) were used following heat based antigen
retrieval (Vector Laboratories). Antibody was detected
using aVectastain ABC kit (Vector Laboratories), visualized
with DAB (Vector Laboratories) and counterstaining was
performed with hematoxylin. For immunofluorescence,
sections were stained using the TUNEL kit (Promega,
Madison, WI) according to the manufacturer’s protocol.
Tissue Microarrays (TMAs)
TMAs, which were approved by the UMN Institutional
Review Board, were obtained from the UMN BioNet
Core Facility as described previously [39]. Areas of DCIS
were verified by a pathologist and coded specimens and
data were provided for this study. All patient identifica-
tion was redacted and not available to authors per
BioNet IRB approval. A total of 17 normal and 31 DCIS
samples were analyzed for EREG and MMP-1 expres-
sion. Due to technical issues including loss of sample
and different core areas, combined analysis included 11
normal and 20 DCIS samples.
Statistics
Statistical analysis was performed using the unpaired
student’s t-test to compare two means. Error bars repre-
sent the standard error of the mean. For the human
samples, the association between EREG and MMP-1 was
evaluated using the Chi-squared test.
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Additional file 1: Figure S1. Coomassie stained gels for loading
controls. A) Loading control for Fig. 5b. B) Loading control for Fig. 5d.
C) Loading control for Fig. 6b.
Additional file 2: Table S1. Primer sequences used for quantitative
RT-PCR.
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